Email this article A study of prevalence of polymorphic variants of genes of blood coagulation factors in onco-logical patients
- Authors: Zykova T.A.1, Vladimirova L.Y.1, Katelnitskaya O.V.1, Maslov A.A.1, Shevyakova E.A.1, Lysenko I.B.1, Abramova N.A.1, Storozhakova A.E.1, Popova I.L.1, Novoselova K.A.1, Tikhanovskaya N.M.1, Lyanova A.A.1, Ryadinskaya L.A.1, Tishina A.V.1, Tishchenko I.S.1, Kabanov S.N.1, Kalabanova E.A.1
-
Affiliations:
- Rostov Research Institute of Oncology
- Issue: Vol 28, No 1 (2020)
- Pages: 44-56
- Section: Original study
- URL: https://bakhtiniada.ru/pavlovj/article/view/16376
- DOI: https://doi.org/10.23888/PAVLOVJ202028144-56
- ID: 16376
Cite item
Abstract
Aim. To study the prevalence of carriage of polymorphic allele variants of genes of blood coagulation factors in oncological patients.
Materials and Methods. 213 Patients with morphologically confirmed oncological diseases were examined. Samples of genomic DNA of peripheral blood of the patients were examined. Using polymerase chain reaction (PCR), polymorphic sites of genes of hemostatic system were studied in real time: F2 (G20210А, rs1799963), F5 (G1691A, rs6025), F7 (G10976A, rs6046), F13 (G226A, rs5985), FGB G(-455)A (rs1800790), ITGA2-α2 (C807T, rs1126643), ITGB3-b (Т1565С, rs5918), PAI-1 4G(-675)5G, rs1799889).
Results. The prevalence of carriage of alternative allele of F2 (G20210А) polymorphic locus in the studied group was 1.6%, of F5 (G1691A) – 3.5%, of F7 (G10976A) – 13.4%, of F13 (G226A) – 28.2%, of FGB G(-455)A – 24.9%, of ITGA2-α2 (C807T) – 41.5%, of ITGB3-b (Т1565С) – 15.5%, of PAI-1 4G(-675)5G – 56.6%. A statistically significant increase in the frequency of ‘risk alleles’ of F5 G1691A (р=0.0169), F13 G226A (р=0.0007), FGB G(-455)A (р<0.0001) and ITGA2-α2 C807T (р=0.0201) polymorphic loci was found in oncological patients as compared to the general population. In the same loci, except ITGA2-α2 (C807T), statistically significant differences in the frequency of alternative alleles were found in different localizations of the oncological process. In 92.0% of patients, SNR combination was determined in different components of hemostatic system.
Conclusion. Taking into account a high frequency of identification of ‘risk alleles’ in all components of hemostatic system, it is reasonable to carry out additional research to determine the necessity of addition of antiaggregants to antithrombotic therapy in oncological patients.
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana A. Zykova
Rostov Research Institute of Oncology
Author for correspondence.
Email: tatiana2904@yandex.ru
ORCID iD: 0000-0001-5345-4872
SPIN-code: 7054-0803
Scopus Author ID: 57200075494
ResearcherId: U-3559-2019
MD, PhD, Head of the Laboratory of Virology
Russian Federation, Rostov- on-DonLyubov Yu. Vladimirova
Rostov Research Institute of Oncology
Email: rnioi@list.ru
ORCID iD: 0000-0003-4236-6476
SPIN-code: 4857-6202
ResearcherId: U-8132-2019
MD, PhD, Professor, Head of the Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonOksana V. Katelnitskaya
Rostov Research Institute of Oncology
Email: Katelnitskayaov@rnioi.ru
MD, PhD, Cardiovascular Surgeon of the Department of Abdominal Oncology № 2
Russian Federation, Rostov-on-DonAndrey A. Maslov
Rostov Research Institute of Oncology
Email: Maslovaa@rnioi.ru
ORCID iD: 0000-0003-4902-5789
SPIN-code: 5963-5915
ResearcherId: W-5180-2019
MD, PhD, Professor, Honored Doctor of the Russian Federation, Chief Physician, Head of the Department of Abdominal Oncology №3
Russian Federation, Rostov-on-DonElena A. Shevyakova
Rostov Research Institute of Oncology
Email: Shevyakovaea@rnioi.ru
ORCID iD: 0000-0002-4232-6733
SPIN-code: 9595-7616
ResearcherId: U-3551-2019
Biologist of Laboratory Virology
Russian Federation, Rostov-on-DonIrina B. Lysenko
Rostov Research Institute of Oncology
Email: Lysenkoib@rnioi.ru
ORCID iD: 0000-0003-4457-3815
SPIN-code: 9510-3504
MD, PhD, Head of the Department of Oncohematology
Russian Federation, Rostov-on-DonNatalia A. Abramova
Rostov Research Institute of Oncology
Email: Abramovana@rnioi.ru
ORCID iD: 0000-0001-7793-9794
SPIN-code: 1784-8819
ResearcherId: U-6181-2019
MD, PhD, Oncologist of Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonAnna E. Storozhakova
Rostov Research Institute of Oncology
Email: Storozhakovaae@rnioi.ru
MD, PhD, Head of the Department of Anticancer Drug Therapy №2
Russian Federation, Rostov-on-DonIrina L. Popova
Rostov Research Institute of Oncology
Email: Popovail@rnioi.ru
ORCID iD: 0000-0003-4865-8832
SPIN-code: 4542-1937
ResearcherId: U-6397-2019
MD, PhD, Oncologist of the Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonKristina A. Novoselova
Rostov Research Institute of Oncology
Email: Novoselovaka@rnioi.ru
ORCID iD: 0000-0002-7059-9026
SPIN-code: 3492-1620
ResearcherId: V-1130-2017
MD, PhD, Oncologist of the Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonNatalya M. Tikhanovskaya
Rostov Research Institute of Oncology
Email: Tikhanovskayanm@rnioi.ru
ORCID iD: 0000-0001-5139-2639
SPIN-code: 9000-4877
ResearcherId: U-8128-2019
Oncologist of the Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonAza A. Lyanova
Rostov Research Institute of Oncology
Email: Lyanovaaa@rnioi.ru
Oncologist of the Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonLyudmila A. Ryadinskaya
Rostov Research Institute of Oncology
Email: Ryadinskayala@rnioi.ru
ORCID iD: 0000-0002-5964-2513
SPIN-code: 6146-2396
ResearcherId: U-6199-2019
MD, PhD, Oncologist of the Department of Anticancer Drug Therapy №1
Russian Federation, Rostov-on-DonAnna V. Tishina
Rostov Research Institute of Oncology
Email: Tishinaav@rnioi.ru
ORCID iD: 0000-0002-7990-8710
SPIN-code: 7686-3707
ResearcherId: H-2460-2018
Oncologist of the Department of Anticancer Drug Therapy №2
Russian Federation, Rostov-on-DonIrina S. Tishchenko
Rostov Research Institute of Oncology
Email: Tishchenkois@rnioi.ru
ORCID iD: 0000-0002-4990-0881
SPIN-code: 7705-2954
ResearcherId: W-5183-2019
Surgeon of the Department of Thoracic Surgery
Russian Federation, Rostov-on-DonSergey N. Kabanov
Rostov Research Institute of Oncology
Email: Kabanovsn@rnioi.ru
MD, PhD, Oncologist of the Department of Anticancer Drug Therapy №2
Russian Federation, Rostov-on-DonElena A. Kalabanova
Rostov Research Institute of Oncology
Email: Kalabanovaea@rnioi.ru
ORCID iD: 0000-0003-0158-3757
SPIN-code: 9090-3007
ResearcherId: V-2943-2019
MD, PhD, Oncologist of the Department of Anticancer Drug Therapy №2
Russian Federation, Rostov-on-DonReferences
- Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. Journal of Thrombosis and Haemostasis. 2009;Suppl. 1:301-4. doi: 10.1111/j.1538-7836.2009. 03394.x
- Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis. 2007;5(4):692-9. doi: 10.1111/j.1538-7836.2007.02450.x
- Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350(25):2558-63. doi: 10.1056/NEJMoa032959
- Vorobev AV, Makatsaria AD, Chabrov AM, et al. Pathogenesis of Trousseau’s syndrome. Journal of Obstetrics and Woman’s Diseases. 2015;64(4):85-94. (In Russ).
- Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thrombosis Research. 2018;164 (Suppl 1):S54-S61. doi: 10.1016/j.thromres.2018.01.017
- Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer pa-tients and the general population: a population-based cohort study in Denmark, 1997-2006. British Journal of Can-cer. 2010;103(7):947-53. doi: 10.1038/sj.bjc.6605883
- Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Archives of Internal Medicine. 2006;166(4):458-64. doi:10.1001/ archinte.166.4.458
- Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalte-parin for up to 12 months: the DALTECAN study. Journal of Thrombosis and Hae-mostasis. 2015;13(6):1028-35. doi: 10.1111/jth.12923
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Medicine. 2012;9 (7):e1001275. doi: 10.1371/journal.pmed.1001275
- Li M, Guo Q, Hu W. Incidence, risk factors, and out comes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis. Thrombosis Research. 2019;173:48-56. doi: 10.1016/j.thromres.2018.11.012
- Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-7. doi: 10.1182/blood-2013-04-460162
- Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-23. doi: 10.1182/blood-2013-04-460121
- Vossen CY, Hoffmeister M, Chang-Claude JC, et al. Clotting factor gene polymorphisms and colorectal cancer risk. Journal of Clinical Oncology. 2011;29(13):1722-7. doi: 10.1200/JCO.2010.31.8873
- Tinholt M, Viken MK, Dahm AE, et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer. 2014;14:845. doi: 10.1186/1471-2407-14-845
- Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-22. doi:10.1001/ jama.293.6.715
- Vorobev AV, Chabrov AM, Savchenko AA., et al. Pathogenesis of Trousseau's syndrome. Obstetrics, Gynecology and Reproduction. 2015;9(2):99-109. (In Russ). doi: 10.17749/2070-4968.2015.9.2.099-109
- Smigielski EM, Sirotkin K, Ward M, et al. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Re-search. 2000;28(1):352-5. doi:10. 1093/nar/28.1.352
- Kit OI, Katelnitskaya OV, Guskova NK, et al. Experience with the treatment of venous thromboembolism in oncolo-gy patients with the use of dabigatran. Flebologiya. 2016;10(1):29-34. (In Russ). doi: 10.17116/flebo201610129-34
- Strozenko LA, Gordeev VV, Lobanov YF, et al. Frequency of carriage of the polymorphic gene variants of clotting factors in adolescents in Barnaul. Siberian Medical Review. 2015;(3):53-6. (In Russ).
- Lobastov KV, Barinov VE, Schastlivtsev IV, et al. Sovremennye podkhody k diagnostike i terapii ostrogo venoznogo tromboza. Moscow: Triumf; 2016. (In Russ).
- Pizova NV. Trombofilii: geneticheskie polimorfizmy i sosudistye katastrofy. Moscow: IMA-PRESS; 2013. (In Russ).
Supplementary files
